Ethambutol/isoniazid/pyrazinamide/rifampicin

Ethambutol/isoniazid/pyrazinamide/rifampicin, also known as ethambutol/isoniazid/pyrazinamide/rifampin, is a medication used for tuberculosis.[1] It is a fixed dose combination of ethambutol, isoniazid, pyrazinamide, and rifampicin.[1] It is used either alone or with other antituberculosis medication.[1] It is taken by mouth.[1]

Ethambutol/isoniazid/pyrazinamide/rifampicin
Combination of
EthambutolAnti-tuberculosis medication
IsoniazidAnti-tuberculosis medication
PyrazinamideAnti-tuberculosis medication
RifampicinAnti-tuberculosis medication
Clinical data
Trade namesVoractiv, Rimstar, others
ATC code
Identifiers
ChemSpider
  • none

Side effects are those of the underlying medications.[1] Pyridoxine may be used to decrease the risk of numbness.[2] It is not recommended in people with liver problems or severe kidney problems.[3] Use may not be suitable in children.[1] It is unclear if use during pregnancy is safe.[3]

It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system.[4] In the United Kingdom it costs the NHS 98.75 pounds for a typical month of medication as of 2015.[2] It is sold under the brand names Voractiv and Rimstar in the UK.[3]

References

  1. World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 142. hdl:10665/44053. ISBN 9789241547659.
  2. British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 403. ISBN 9780857111562.
  3. "Rimstar Film-coated Tablet / Voractiv Film-coated Tablet - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. February 2016. Archived from the original on 20 December 2016. Retrieved 18 December 2016.
  4. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.